| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911108 | Lung Cancer | 2014 | 7 Pages |
Abstract
Patients with advanced NS-NSCLC eligible for Bev-treatment may derive clinical benefit at acceptable toxicity from the addition of Bev to both Pem-Cis induction and Pem maintenance therapy; however, this is not an approved combination regimen.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Armando Santoro, Gunnar N. Hillerdal, Gert Hoeffken, Adolfo Favaretto, Ramon Perez Carrion, Carla Visseren-Grul, Sophie Ameryckx, Karin Helsberg, Victoria Soldatenkova, Nawel Bourayou, Jens B. Sørensen,